Program planning and continual evaluation have been critical for the development of the Cancer Therapy & Research Center (CTRC) and its research infrastructure. CTRC uses both internal and external sources for review and evaluation, soliciting input from Cancer Center experts. The CTRC External Advisory Board is the primary external mechanism for review and advice on the CTRC and its progress in both clinical and basic research. CTRC has also utilized smaller ad hoc advisory groups for Cancer Center Administration, Shared Resources and Programs. Internal mechanisms for planning and evaluation center around the CTRC Executive Committee (EC), which includes the CTRC Associate Directors and Program Leaders, as well as the CTRC Internal Advisory Board (lAB) and the CTRC Shared Resources Oversight Committee. The lAB includes Senior Leaders from the University of Texas Health Science Center (UTHSCSA), who meet annually to provide feedback on CTRC's progress in clinical and research arenas at the UTHSCSA. The Shared Resources Oversight Committee aids the Center through annual evaluation of the CTRC Shared Resources as well as by making recommendations with respect to CTRC Shared Resources. ! A key part of the CTRC planning and evaluation process has been the development of a CTRC Strategic Plan. A number of groups including those mentioned above have had a role in the strategic planning process. The CTRC Strategic Plan was developed and organized in accordance with the Six Essential Characteristics of NCI-Designated Cancer Centers. A critical element of the CTRC Strategic Plan is the renewed focus of the CTRC on serving its catchment area and understanding cancer in our predominantly Hispanic population. Other areas of focus include expansion of team science in the CTRC, outreach to other institutions of higher education in the area, and targeted recruitment of faculty to build the clinical and research enterprise of the CTRC.

Public Health Relevance

The continuously ongoing planning and evaluation processes of the CTRC have been a critical component of the rebuilding that has occurred over the past funding period. A sustained focus on the CTRC Strategic Plan will be key to its growth and success.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA054174-20
Application #
8758434
Study Section
Special Emphasis Panel (ZCA1-RTRB-A (M3))
Project Start
1997-08-01
Project End
2019-07-31
Budget Start
2014-09-16
Budget End
2015-07-31
Support Year
20
Fiscal Year
2014
Total Cost
$56,779
Indirect Cost
$39,732
Name
University of Texas Health Science Center
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Yu, Xiaojie; Zhang, Yiqiang; Cavazos, David et al. (2018) miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer. Cell Death Dis 9:193
Chen, Chen; Zhao, Shujie; Karnad, Anand et al. (2018) The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 11:64
Abbott, Jamie A; Meyer-Schuman, Rebecca; Lupo, Vincenzo et al. (2018) Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. Hum Mutat 39:415-432
Guo, Jiayan; Kim, Hong Seok; Asmis, Reto et al. (2018) Interactions of ? tubulin isotypes with glutathione in differentiated neuroblastoma cells subject to oxidative stress. Cytoskeleton (Hoboken) 75:283-289
Liss, Michael A; Chen, Yidong; Rodriguez, Ronald et al. (2018) Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. Urology :
Zhu, Haiyan; Xia, Lu; Shen, Qi et al. (2018) Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. Lab Invest 98:1384-1396
Zeno, Wade F; Baul, Upayan; Snead, Wilton T et al. (2018) Synergy between intrinsically disordered domains and structured proteins amplifies membrane curvature sensing. Nat Commun 9:4152
Mahalingam, Devalingam; Goel, Sanjay; Aparo, Santiago et al. (2018) A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 10:
Yu, Xiaojie; Zhang, Yiqiang; Ma, Xiuye et al. (2018) miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett 427:85-93
Ankerst, Donna P; Goros, Martin; Tomlins, Scott A et al. (2018) Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus :

Showing the most recent 10 out of 989 publications